CSLLY Company Profile and Key Details

Q: Who are the executives of CSLLY?

Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFIChief Financial OfficerDr. Wilfried FreudenbergDepartment Head of Albumin & Immunoglobulins ProductionDr. Paul F. McKenzie Ph.D.MD, Chief Executive Officer & Executive DirectorMr. Paul R. Perreault B.A.Strategic AdvisorMr. William Campbell B.S.Executive Vice President & Chief Commercial OfficerDr. Karen EtchbergerExecutive Vice President of Quality & Bus. ServicesMs. Jemimah BrennanHead of Communications - Asia PacificChristina HickieSenior Mang. of CommunicationsMs. Elizabeth Walker B.A., M.S.Executive Vice President & Chief HR OfficerMr. Gregory Boss B.S., BS(Hons), J.D.Executive Vice President of Legal & Group Gen. CounselMr. Mark DehringHead of Investor Relations

PNK : CSLLY

CSL

$95.35

0.75+0.79%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CSL Limited (CSLLY) stock declined over -0.67%, trading at $25.88 on OTC, down from the previous close of $26.06. The stock opened at $52.00, fluctuating between $25.50 and $52.08 in the recent session.

Stock Snapshot

26.055

Prev. Close

100.22B

Market Cap

25.5

Day Low

8.4

P/E Ratio

3.08

EPS (TTM)

Cash Flow per Share

Open

3.87B

Number of Shares

52.08

Day High

99.98%

Free Float in %

17.79

Book Value

4.9K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	52.00	52.08	25.50	26.00	61.62K
Feb 27, 2026	52.00	52.12	51.85	52.08	94.52K
Feb 26, 2026	53.96	53.96	51.45	51.85	199.38K
Feb 25, 2026	51.43	51.80	51.37	51.79	90.66K
Feb 24, 2026	51.08	52.20	50.85	50.95	248.31K
Feb 23, 2026	53.21	53.21	51.92	52.11	224.05K
Feb 20, 2026	54.00	54.28	53.70	54.15	148.08K
Feb 19, 2026	53.91	54.22	53.91	54.02	89.42K
Feb 18, 2026	53.89	54.16	53.67	53.87	182.72K
Feb 17, 2026	52.26	53.57	52.26	53.00	300.45K
Feb 13, 2026	53.10	53.80	52.95	53.00	102.5K
Feb 12, 2026	54.86	54.86	53.47	53.77	104.62K
Feb 11, 2026	58.17	58.58	56.68	57.95	58.82K
Feb 10, 2026	61.00	67.06	57.19	58.99	227.22K
Feb 09, 2026	64.01	64.54	63.76	64.47	171.97K
Feb 06, 2026	61.11	65.82	61.11	64.22	210.05K
Feb 05, 2026	63.59	65.38	62.64	63.01	391.64K
Feb 04, 2026	64.09	64.94	63.60	64.25	540.42K
Feb 03, 2026	62.38	66.68	62.09	63.03	68.39K
Feb 02, 2026	62.08	62.40	61.97	62.07	97.21K

Contact Details

Melbourne, VIC 3052

Australia

https://www.csl.com.au 613 938 91911

About Company

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 FNCH

-0.05-0.38%

Finch Therapeutics Group, Inc.$13.20 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

CSL Limited (OTC:CSLLY) closed at $25.88 USD, losing -$0.18 (-0.67%) from the previous close of $26.05. The stock is currently within 5% of its 52-week low $25.43 and $52.08. With a market capitalization of about $100.22 billion, CSL Limited is classified as a large-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 302.64 thousand shares, volume is running light vs its 52-week average. Headquartered in Melbourne, VIC, CSL Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gordon Naylor DipCompSc, the company employs approximately 32,698 people and listed since December 29, 2009. CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

Technical Performance

Average 10-day trading volume of 153.09 thousand shares is in line with the 3-month average of 148.45 thousand, indicating normal recent market interest.

Valuation Metrics

CSL Limited trades at a P/E ratio of 70.08, slightly above the S&P 500 average, with a price-to-sales ratio of 6.46 and a price-to-book ratio of 5.38 trading at moderately above to book value. The P/FCF stands at 31.78, also below market averages.

Dividend & Fair Value

CSL Limited last paid a dividend of 0.73 per share, this equals a trailing yield of roughly 2.64%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $29.88. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, CSL generated $15.43B in revenue, or $31.75 per share. Gross margin was 51.53%, operating margin 19.18%, and net profit margin 19.46%. Returns are healthy, with ROA at 7.62% and ROE at 15.53%.
On valuation metrics, CSL trades at a P/E of 70.08, P/S of 6.46 and P/B of 5.38. The current ratio is 2.57 and quick ratio is 1.15. Operationally, the company’s inventory turnover is 1.22 and cash conversion cycle is 252.19 days. Debt-to-equity is 0.67, supported by a cash flow-to-debt ratio of 0.30.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, CSL posted revenue of $15.43B, down slightly from $14.69B in the prior quarter. Gross profit was $7.95B (margin 51.53%). Operating income was $2.96B (margin 19.2%). Net income was$3.00B (EPS $6.20).
The company ended the quarter with $2.16B in cash and short-term investments, a total debt of $11.50B, and net debt of $9.34B. Total assets were $39.40B, with equity of $19.34B. Financials further reflected stability, with operating cash flow of $3.56B, free cash flow of $2.54B, and capital expenditures of - $1.02B.

Price Forecast & Outlook

Our AI price prediction model suggests that CSL Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows CSL Limited trading at a premium to the broader market with a P/E of 70.08.

Frequently Asked Questions

What is the current CSL Limited (CSLLY) stock price?

CSL Limited (OTC: CSLLY) stock price is $25.88 in the last trading session. During the trading session, CSLLY stock reached the peak price of $52.08 while $25.50 was the lowest point it dropped to. The percentage change in CSLLY stock occurred in the recent session was -0.67% while the dollar amount for the price change in CSLLY stock was - $0.18.

CSLLY's industry and sector of operation?

The OTC listed CSLLY is part of Biotechnology industry that operates in the broader Healthcare sector. CSL Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CSLLY?

Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI
Chief Financial Officer
Dr. Wilfried Freudenberg
Department Head of Albumin & Immunoglobulins Production
Dr. Paul F. McKenzie Ph.D.
MD, Chief Executive Officer & Executive Director
Mr. Paul R. Perreault B.A.
Strategic Advisor
Mr. William Campbell B.S.
Executive Vice President & Chief Commercial Officer
Dr. Karen Etchberger
Executive Vice President of Quality & Bus. Services
Ms. Jemimah Brennan
Head of Communications - Asia Pacific
Christina Hickie
Senior Mang. of Communications
Ms. Elizabeth Walker B.A., M.S.
Executive Vice President & Chief HR Officer
Mr. Gregory Boss B.S., BS(Hons), J.D.
Executive Vice President of Legal & Group Gen. Counsel
Mr. Mark Dehring
Head of Investor Relations

How CSLLY did perform over past 52-week?

CSLLY's closing price is 33.34% higher than its 52-week low of $25.43 where as its distance from 52-week high of $52.08 is -4.6%.

How many employees does CSLLY have?

Number of CSLLY employees currently stands at 32,698.

Link for CSLLY official website?

Official Website of CSLLY is: https://www.csl.com.au

How do I contact CSLLY?

CSLLY could be contacted at phone 613 938 91911 and can also be accessed through its website. CSLLY operates from 45 Poplar Road, Melbourne, VIC 3052, Australia.

How many shares of CSLLY are traded daily?

CSLLY stock volume for the day was 4.9K shares. The average number of CSLLY shares traded daily for last 3 months was 302.64K.

What is the market cap of CSLLY currently?

The market value of CSLLY currently stands at $100.22B with its latest stock price at $25.88 and 3.87B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	32698
Beta	0.28
Sales or Revenue	$15.43B
5Y Sales Change%	0.538%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

CSLLY Company Profile and Key Details

CSL

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook